AlphAIalphai — Financial news for AI agents
BenzingaNOV 133 min read$AMRXBullishHigh

Amneal Receives U.S. FDA Approval for Iohexol Injection - Amneal Pharmaceuticals (NASDAQ:AMRX)

BRIDGEWATER, N.J., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) ( NASDAQ:AMRX ) today announced the U.S. Food and Drug Administration ( FDA ) has approved the Company's iohexol injection ( 300 mg Iodine/mL ) , the first generic version of GE ...

Globe NewswireNovember 13, 2025
Source · www.benzinga.com
AI analysis
Relevance
0/10
Actionability
High
Sentiment · $AMRX
Bullish
Timing
Immediate to short-term (next 1-4 weeks)
Market alignment
Aligns with positive sentiment from FDA approval news
Why this matters for $AMRX

The FDA approval of Amneal's iohexol injection positions the company favorably within the generic pharmaceuticals market, potentially leading to increased sales and revenue growth.

Relevance context

The news pertains directly to Amneal Pharmaceuticals and its recent FDA approval, which is highly relevant for trading decisions.

Price-impact prediction

Moderate upward movement expected in the short to medium term.

Background

Amneal's recent FDA approval marks a significant milestone, as it is the first generic version of GE's iohexol injection, a widely used contrast agent.

Why it matters

This approval could lead to increased revenues and market share for Amneal, but success depends on effective commercialization and market acceptance.

Market relevance

The news is highly relevant for investors in Amneal and the broader pharmaceutical sector, signaling potential growth opportunities.

Market effects

Sector

The approval could positively influence the biotech and pharmaceutical sectors, especially companies involved in generic drug manufacturing.

Regional

Primarily US-focused impact, with potential ripple effects in global markets due to industry competitiveness.

Global

Moderate; while primarily US regulatory approval, it may influence global generic drug markets.

Alternative perspectives

Contrarian view

The FDA approval may already be priced into the stock, and any delays or market skepticism could limit upside potential.

Overlooked factors

Potential competition from other generic manufacturers and market acceptance of the new product could influence actual sales performance.

Key entities

  • Company
    Amneal Pharmaceuticals

    A pharmaceutical company focused on generic and specialty medicines.

  • Regulatory Agency
    FDA

    U.S. Food and Drug Administration, responsible for drug approvals.

  • Company
    GE Healthcare

    The original manufacturer of the iohexol injection.

Read at source← All news

Related articles

JUN 4
$AMRXMedAI 9/10

Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution

Amneal Pharmaceuticals said the FDA approved its ready-to-use romidepsin injection solution (27.5 mg/5.5 mL) in single-dose vials. The drug received Competitive Generic Therapy (CGT) designation, granting Amneal 180 days of market exclusivity. Amneal said the product references a Teva romidepsin liquid previously withdrawn. IQVIA data cited about $78 million in U.S. sales for the prior lyophilized form.

proactiveinvestors.com4 min
JUN 4
$AMRXMedAI 9/10

Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution

Amneal Pharmaceuticals said the U.S. FDA approved its romidepsin injection solution (27.5 mg/5.5 mL) in single-dose, ready-to-use vials. The product is eligible for Competitive Generic Therapy status, granting 180 days of market exclusivity, and references a former Teva formulation. IQVIA data cited by Amneal put U.S. sales of romidepsin lyophilized powder at about $78 million for 12 months ended April 2026.

manilatimes.net4 min